ReachRxResearch
Home
Research
Sign Up
MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Back to Research Hub
  1. Home
  2. Research Hub
  3. MRI Characteristics of Myelin Oligodendr…

MRI Characteristics of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

JAMA Neurology·September 28
Clinical NeurologyPractice changingDemyelinating DiseaseMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseNarrative ReviewMRI NeuroimagingMixed

Summary

View source

What was studied

This review summarizes the hallmark MRI features, lesion dynamics, and diagnostic protocols for myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), contrasting it with MS and AQP4+NMOSD, and covering emerging AI and advanced imaging applications.

Key findings

MOGAD shows characteristic MRI findings including frequent T2-lesion resolution, rare asymptomatic radiological activity, and radiologic lag during acute attacks — patterns that differ meaningfully from the persistent lesions and subclinical activity seen in MS. A standardized MRI protocol for acute attacks is proposed.

Study limitations

This is a narrative review without a systematic search or meta-analysis; no original patient-level data are reported, so quantitative effect estimates are absent. Evidence underpinning specific recommendations is not graded explicitly.

Clinical implications

Recognize that MOGAD lesions frequently resolve on T2 MRI and asymptomatic radiological activity is rare, making routine surveillance MRI less useful than in MS. Use the proposed standardized acute-attack MRI protocol and consider rebaselining MRI after symptom onset to avoid misdiagnosis.

Caveats

  • Full text was not accessible; extraction is based solely on the abstract and publisher page text, so detailed MRI protocol specifics, figures, and tables referenced in the review could not be assessed
  • MOGAD is a relatively newly defined entity; some MRI criteria cited are from the 2023 diagnostic criteria, which themselves may still be evolving
  • This is an expert narrative review, not a systematic review or meta-analysis; recommendations reflect author consensus and may not be graded by evidence level

Related Questions

Explore related topics

How do I differentiate MOGAD from MS and AQP4+ NMOSD on MRI?What is the recommended MRI protocol for an acute MOGAD attack?Does maintenance immunotherapy reduce relapse risk in MOGAD?

Publication Details

Year
2026
Journal
JAMA Neurology
Source
View article
Keep scrolling
More content below.
Up Next